Lyka Labs informs about disclosure

10 Oct 2023 Evaluate
Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; Lyka Labs has informed that, the Company has received the product permission from the Central Drugs Standard Control Organization of India to Manufacture and Market Tofacitinib Ointment 2% w/w. The Company has received this permission after successfully completing the Clinical Trial on 125 patients across 8 Clinical Trial Centers within India.

The above information is a part of company’s filings submitted to BSE.

Lyka Labs Share Price

143.35 2.55 (1.81%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.